Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells

BACKGROUND: The advances in colorectal cancer (CRC) treatment include the identification of deficiencies in Mismatch Repair (MMR) pathway to predict the benefit of adjuvant 5-fluorouracil (5-FU) and oxaliplatin for stage II CRC and immunotherapy. Defective MMR contributes to chemoresistance in CRC....

Descripción completa

Detalles Bibliográficos
Autores principales: de Castro e Gloria, Helena, Jesuíno Nogueira, Laura, Bencke Grudzinski, Patrícia, da Costa Ghignatti, Paola Victória, Guecheva, Temenouga Nikolova, Motta Leguisamo, Natalia, Saffi, Jenifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063290/
https://www.ncbi.nlm.nih.gov/pubmed/33888065
http://dx.doi.org/10.1186/s12885-021-08188-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063290/
https://www.ncbi.nlm.nih.gov/pubmed/33888065
http://dx.doi.org/10.1186/s12885-021-08188-7

Ejemplares similares